Diabetes Act
Senate bill addresses diabetes prevention and treatment access, likely focusing on healthcare costs and medication affordability through insurance policy reforms.
Senate bill addresses diabetes prevention and treatment access, likely focusing on healthcare costs and medication affordability through insurance policy reforms.
S 4037, the Diabetes Act, is a Senate bill introduced by Senators Jeanne Shaheen and Susan Collins that addresses diabetes prevention, treatment, and management in the United States. The bill was referred to the Committee on Finance on March 10, 2026, following its introduction. Specific legislative provisions are not detailed in the available information.
Diabetes affects approximately 37 million Americans and is a leading cause of death and disability, making policy interventions potentially significant for public health outcomes. Finance committee referral suggests the bill likely addresses insulin pricing, Medicare/Medicaid coverage, or other cost-related aspects of diabetes care—issues that directly impact patient access and affordability. Given bipartisan sponsorship, the bill may reflect broader congressional concern about diabetes management costs.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.